What is Zacks Research’s Estimate for Pfizer Q2 Earnings?

Pfizer Inc. (NYSE:PFE) – Equities researchers at Zacks Research cut their Q2 2026 earnings estimates for Pfizer in a report released on Thursday, March 20th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will earn $0.57 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s FY2027 earnings at $2.96 EPS.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS.

A number of other equities analysts have also recently issued reports on PFE. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 2.2 %

Shares of NYSE PFE opened at $25.56 on Monday. The firm’s fifty day moving average is $26.14 and its 200 day moving average is $27.00. Pfizer has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $144.96 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 0.64 and a beta of 0.61.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC lifted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the fourth quarter worth approximately $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.